Full Press Release Details
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating
Officer and Transition of Dr. Florian von der M lbe to Lead Accelerated Development of The RNA Printer
T BINGEN, Germany / BOSTON, USA - June 30, 2021
- CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines
based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Dr. Malte Greune as Chief Operating Officer
(COO) effective July 1, 2021. In this position, he will strengthen the company's Management Board and will head, among others,
CureVac's clinical and commercial manufacturing activities. Dr. Greune joins CureVac with extensive experience in the global pharmaceutical
industry, including manufacturing of vaccines and fill & finish of biologics.
CureVac also announced that Dr. Florian von der M lbe, co-founder
and Chief Production Officer, will now focus his extensive production expertise exclusively on the expansion and accelerated development
of The RNA Printer , CureVac's solution for mobile, autonomous and fully automated manufacturing of GMP-grade RNA vaccines
and therapeutics. To drive this key strategic project forward, which requires building its own operational infrastructure, Dr. von der
M lbe will resign from the Management Board of CureVac N.V. Dr. Greune will assume Dr. von der M lbe's position on the
"On behalf of the Supervisory Board I would like to welcome
Dr. Greune to the Management Board. Dr. Greune is a recognized expert in the global pharmaceutical industry with many years of experience
in various management positions. His appointment is a great asset for CureVac as the company continues to grow, further expanding its
one-stop shop strategy for RNA-based vaccines and therapeutics with strong manufacturing capabilities," said Jean St phenne,
Chairman of the Supervisory Board of CureVac. "I would like to thank Dr. von der M lbe for his service on the CureVac Management
Board. As a co-founder of CureVac, he has played a key role in building the company and establishing its strong manufacturing expertise
that he will now transition to ensure The RNA Printer becomes another key growth driver for the company."
Dr. Greune joins CureVac from Sanofi Aventis Deutschland GmbH where
he held various management positions for almost ten years. As General Manager and Vice President Cartridges, Devices & Insulin Technology
Group he was responsible for several manufacturing sites in Frankfurt. Under his leadership, six isolator filling lines for insulins,
oncology drugs and biologics were set up including one for a COVID-19 vaccine. Prior to his position as Head of Diabetes, Oncology and
Devices at Sanofi, he worked as Senior Vice President of Animal Health Manufacturing for the Merck Manufacturing Division, USA, where
he led an international network of 28 sites - including 18 integrated vaccine sites. Furthermore, he held various leadership roles
at the pharmaceutical companies Schering-Plough and Intervet International B.V. Dr. Greune started his career at Hoechst AG in Corporate
Planning. Dr. Greune received his Ph.D. in Economics from the University of Cologne, Germany, graduated from the University of Trier,
Germany, and completed a Master of Business Administration at Clark University in Worcester, USA.
"Dr. Greune has a broad range of expertise in the international
pharmaceutical sector which will benefit CureVac's growth even further," said Dr. Franz-Werner Haas, Chief Executive Officer
of CureVac. "We are confident that his outstanding experience will support us in accelerating our development from a science-driven
to a commercial pharmaceutical company. I would like to thank Dr. Florian von der M lbe for combining founder s mindset with
a growing commercialized company which he will continue to provide by the accelerated development of The RNA Printer ."
"Strong manufacturing capabilities represent an important part
of our corporate strategy and I am proud of what we have built-up together in this area over the last 21 years," said Dr. Florian
von der M lbe. "I am happy that Dr. Greune is taking over to further develop our manufacturing capabilities and I am looking
forward to using all my strength and expertise to rapidly drive forward The RNA Printer as an accelerator of the RNA-field."
"It is a great pleasure to join CureVac at such an exciting
phase of corporate transformation that centers on a diversified RNA-based product pipeline across different indications," added
Dr. Malte Greune. "This technology is just starting to change today's medicine. I am looking forward to taking on this important
task with the goal of bringing multiple mRNA drugs to market which may improve human health worldwide."
CureVac is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile
biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA
as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its
proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody
therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered
in T bingen, Germany, and employs more than 700 people at its sites in T bingen, Frankfurt, and Boston, USA. Further information
can be found at www.curevac.com.
CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor
CureVac, T bingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
CureVac Media Contact
Anna Kamilli, Manager Communications
CureVac, T bingen, Germany
T: +49 7071 9883-1684
Bettina J dicke-Braas, Manager Communications
CureVac, T bingen, Germany
T: 49 7071 9883-1087
Forward-Looking Statements
This press release contains statements that constitute "forward
looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements
that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned
subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the "company")
regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of
the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth
opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate,"
"intend," "believe," "estimate," "plan," "seek," "project," or
"expect," "may," "will," "would," "could," "potential," "intend,"
or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's
current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are
not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements
are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing
instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical
studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration
partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation,
regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects
of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel,
reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the
effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned
not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual
results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made
only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or
to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required
For further information, please reference the company's reports
and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC
website at www.sec.gov.